These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 36071523)

  • 1. Targeting RNA N
    Li W; Hao Y; Zhang X; Xu S; Pang D
    Mol Cancer; 2022 Sep; 21(1):176. PubMed ID: 36071523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncoding RNAs: the shot callers in tumor immune escape.
    Liu L; Wang Q; Qiu Z; Kang Y; Liu J; Ning S; Yin Y; Pang D; Xu S
    Signal Transduct Target Ther; 2020 Jun; 5(1):102. PubMed ID: 32561709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
    Pan J; Huang T; Deng Z; Zou C
    Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
    Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
    Front Immunol; 2021; 12():773570. PubMed ID: 34956201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.
    Zhou X; Li C; Chen T; Li W; Wang X; Yang Q
    Mol Cancer; 2023 Feb; 22(1):36. PubMed ID: 36810108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances of RNA m
    Ma S; Barr T; Yu J
    Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.
    Liu W; Liu C; Wang H; Xu L; Zhou J; Li S; Cheng Y; Zhou R; Zhao L
    Comput Struct Biotechnol J; 2022; 20():5150-5161. PubMed ID: 36187919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N
    Quan C; Belaydi O; Hu J; Li H; Yu A; Liu P; Yi Z; Qiu D; Ren W; Ma H; Gong G; Ou Z; Chen M; Sun Y; Chen J; Zu X
    Front Immunol; 2021; 12():697026. PubMed ID: 34526985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification.
    Sun X; Wang H; Pu X; Wu Y; Yuan X; Wang X; Lu H
    Cancer Gene Ther; 2024 Sep; 31(9):1315-1322. PubMed ID: 38834772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of m
    Wu C; Li L; Tang Q; Liao Q; Chen P; Guo C; Zeng Z; Xiong W
    Med Oncol; 2024 May; 41(6):159. PubMed ID: 38761335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA N
    Zhang Z; Zhang C; Luo Y; Zhang G; Wu P; Sun N; He J
    Clin Transl Med; 2021 Sep; 11(9):e525. PubMed ID: 34586737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the RNA m
    Li X; Ma S; Deng Y; Yi P; Yu J
    Mol Cancer; 2022 Mar; 21(1):76. PubMed ID: 35296338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
    Tong H; Wei H; Smith AO; Huang J
    Front Immunol; 2021; 12():802049. PubMed ID: 35069586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surmounting cancer drug resistance: New insights from the perspective of N
    Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
    Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of m
    Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
    Front Immunol; 2021; 12():782551. PubMed ID: 34975871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of N6-methyladenosine modification in tumor immunity and immunotherapy.
    Zhang Z; Liu F; Chen W; Liao Z; Zhang W; Zhang B; Liang H; Chu L; Zhang Z
    Exp Hematol Oncol; 2022 May; 11(1):30. PubMed ID: 35590394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. m
    Peng C; Xiong F; Pu X; Hu Z; Yang Y; Qiao X; Jiang Y; Han M; Wang D; Li X
    Front Immunol; 2023; 14():1326031. PubMed ID: 38187373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy.
    Shi JX; Zhang ZC; Yin HZ; Piao XJ; Liu CH; Liu QJ; Zhang JC; Zhou WX; Liu FC; Yang F; Wang YF; Liu H
    Mol Cancer; 2024 Sep; 23(1):213. PubMed ID: 39342168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-Methyladenosine Regulator-Mediated Immue Patterns and Tumor Microenvironment Infiltration Characterization in Glioblastoma.
    Xiong W; Li C; Wan B; Zheng Z; Zhang Y; Wang S; Fan J
    Front Immunol; 2022; 13():819080. PubMed ID: 35359993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of m6A modifications on immune cells and immunotherapy.
    Gan L; Zhao Y; Fu Y; Chen Q
    Biomed Pharmacother; 2023 Apr; 160():114343. PubMed ID: 36758318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.